Immunity Induced by Modified Adenovirus Fiber

修饰腺病毒纤维诱导免疫

基本信息

  • 批准号:
    7625061
  • 负责人:
  • 金额:
    $ 41.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-06-15 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal aims to elucidate the role of adenovirus (Ad) capsid fiber protein to stimulate the immune system and to deliver antigens for genetic vaccination. Incorporation of antigens into the Ad capsid is a novel and promising strategy to capitalize on the immunogenic properties of Ad and a way to circumvent preexisting anti-Ad immunity. Preliminary studies show that the most promising site for the integration of an epitope into the Ad capsid is the fiber protein. The overall hypothesis is that incorporation of epitopes in the optimal location of the Ad fiber protein can evoke potent protective anti-epitope immunity even in the presence of anti-Ad immunity. Little is known about the effect of fiber modifications on antigen presentation and anti-Ad immunity. Little is known about the effect of fiber modifications on antigen presentation and anti-Ad immunity. The knowledge gained from the proposed studies will not only be useful in the development of Ad-based vaccines, but also to identify mechanisms of the role the Ad fiber in the immunogenicity of Ad. Two specific aims will test the overall hypothesis: Aim 1 will evaluate the hypothesis that the location of a model epitope within the Ad fiber protein will influence interaction with target cells, antigen presentation and anti-epitope immune responses. Aim 2 will evaluate the hypothesis that epitopes derived from a membrane-bound and secreted antigen of two bacterial pathogens incorporated into an optimal location of the Ad fiber protein can induce protective immunity in the presence of pre-existing anti-Ad immunity. Epitopes from the Pseudomonas aeruginosa outer membrane protein F and the Bacillus anthracis protective antigen will be inserted in the optimal position of the Ad fiber, and evaluated in their potential to elicit cellular, humoral and protective anti-epitope immune responses. New methods for vaccines, as the one proposed here, will be relevant for the public health. They can aid in the development of vaccines for infections against which no or no good vaccines are available. Successful vaccines have had a profound impact on the prevention of infectious diseases over the last century.
描述(由申请方提供):本提案旨在阐明腺病毒(Ad)衣壳纤维蛋白在刺激免疫系统和递送用于基因疫苗接种的抗原方面的作用。将抗原并入到Ad衣壳中是利用Ad的免疫原性的新颖且有前景的策略,并且是规避预先存在的抗Ad免疫的方式。初步研究表明,将表位整合到Ad衣壳中的最有希望的位点是纤维蛋白。总的假设是,在Ad纤维蛋白的最佳位置掺入表位可以引起有效的保护性抗表位免疫,即使在抗Ad免疫的存在下。纤维修饰对抗原呈递和抗Ad免疫的影响知之甚少。纤维修饰对抗原呈递和抗Ad免疫的影响知之甚少。从这些研究中获得的知识不仅将有助于开发基于Ad的疫苗,而且还将有助于确定Ad纤维在Ad免疫原性中的作用机制。两个具体目标将测试总体假设:目标1将评估Ad纤维蛋白内模型表位的位置将影响与靶细胞的相互作用、抗原呈递和抗表位免疫应答的假设。目的2将评估的假设,来自两种细菌病原体的膜结合和分泌的抗原的表位纳入Ad纤维蛋白的最佳位置,可以诱导保护性免疫的存在下,预先存在的抗Ad免疫。将来自铜绿假单胞菌外膜蛋白F和炭疽杆菌保护性抗原的表位插入Ad纤维的最佳位置,并评估其引发细胞、体液和保护性抗表位免疫应答的潜力。这里提出的疫苗新方法将与公共卫生有关。它们可以帮助开发针对没有或没有良好疫苗的感染的疫苗。成功的疫苗对上个世纪传染病的预防产生了深远的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stefan Worgall其他文献

Stefan Worgall的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stefan Worgall', 18)}}的其他基金

Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
SARS-CoV-2 感染对患有和不患有哮喘的儿童呼吸道病毒免疫反应的影响
  • 批准号:
    10568344
  • 财政年份:
    2023
  • 资助金额:
    $ 41.2万
  • 项目类别:
Respiratory sphingolipid synthesis involved in airway hyperreactivity and viral-triggered asthma
呼吸鞘脂合成参与气道高反应性和病毒引发的哮喘
  • 批准号:
    10660726
  • 财政年份:
    2023
  • 资助金额:
    $ 41.2万
  • 项目类别:
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis
通过鞘脂合成抑制剂增强对 RSV 的保护性免疫力
  • 批准号:
    10354486
  • 财政年份:
    2022
  • 资助金额:
    $ 41.2万
  • 项目类别:
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis
通过鞘脂合成抑制剂增强对 RSV 的保护性免疫力
  • 批准号:
    10619550
  • 财政年份:
    2022
  • 资助金额:
    $ 41.2万
  • 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
  • 批准号:
    8662189
  • 财政年份:
    2013
  • 资助金额:
    $ 41.2万
  • 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
  • 批准号:
    9040866
  • 财政年份:
    2013
  • 资助金额:
    $ 41.2万
  • 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
  • 批准号:
    8579420
  • 财政年份:
    2013
  • 资助金额:
    $ 41.2万
  • 项目类别:
Vaccination Against RSV with Capsid-modified Ad Vectors
使用衣壳修饰的广告载体进行 RSV 疫苗接种
  • 批准号:
    7654470
  • 财政年份:
    2009
  • 资助金额:
    $ 41.2万
  • 项目类别:
Vaccination Against RSV with Capsid-modified Ad Vectors
使用衣壳修饰的广告载体进行 RSV 疫苗接种
  • 批准号:
    7847618
  • 财政年份:
    2009
  • 资助金额:
    $ 41.2万
  • 项目类别:
Immunity Induced by Modified Adenovirus Fiber
修饰腺病毒纤维诱导免疫
  • 批准号:
    7447405
  • 财政年份:
    2007
  • 资助金额:
    $ 41.2万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 41.2万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 41.2万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了